about
The stomach in health and diseaseThe quest for biomarkers in IBS-where should it lead us?BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia.What's new in Rome IV?A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitisVisceral hypersensitivity: facts, speculations, and challenges.Free cytosolic Ca2+ recordings from myenteric neurones in multilayer intestinal preparations.Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.Depression and Somatization Are Associated With Increased Postprandial Symptoms in Patients With Irritable Bowel Syndrome.Giovanni Gasbarrini, winner of the UEG Lifetime Achievement Award 2013.Receptors of the enteric nervous system: potential targets for drug therapy.Effect of Prucalopride in the Treatment of Chronic Constipation in Asian and Non-Asian Women: A Pooled Analysis of 4 Randomized, Placebo-controlled Studies.From intestinal permeability to dysmotility: the biobreeding rat as a model for functional gastrointestinal disordersRole of corticosterone in the murine enteric nervous system during fasting.Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis.Pressure flow analysis in the assessment of preswallow pharyngeal bolus presence in Dysphagia.Factors predictive of treatment-emergent adverse events of prucalopride: an integrated analysis of four randomized, double-blind, placebo-controlled trials.Shifting the circadian rhythm of feeding in mice induces gastrointestinal, metabolic and immune alterations which are influenced by ghrelin and the core clock gene Bmal1Ambulatory gastrojejunal manometry in severe motility-like dyspepsia: lack of correlation between dysmotility, symptoms, and gastric emptying.Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in manPerception of changes in wall tension of the proximal stomach in humans.Effects of high-fructose diets on central appetite signaling and cognitive functionThe aging oesophagus.The Gustatory Signaling Pathway and Bitter Taste Receptors Affect the Development of Obesity and Adipocyte Metabolism in Mice.Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate responseTargeting extra-oral bitter taste receptors modulates gastrointestinal motility with effects on satiationRole of the clock gene Bmal1 and the gastric ghrelin-secreting cell in the circadian regulation of the ghrelin-GOAT system.Randomized clinical trial: effect of the 5-HT4 receptor agonist revexepride on reflux parameters in patients with persistent reflux symptoms despite PPI treatment.Characterization of Esophageal Physiology Using Mechanical State AnalysisThe pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying.Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials.Randomised clinical trial: the 5-HT4 agonist revexepride in patients with gastro-oesophageal reflux disease who have persistent symptoms despite PPI therapyNaloxegol for the treatment of opioid-induced constipation.Automatische Impedantie Manometrie (AIM): objectieve diagnostiek van oro-faryngale dysfagie.Impedance as an adjunct to manometric testing to investigate symptoms of dysphagia: What it has failed to do and what it may tell us in the futureNaloxegol , a new drug for the treatment of opioid-induced constipation.Therapeutic options in oesophageal dysphagia.Association between health-related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride.Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome.Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
P50
Q26784036-61B3A72C-7EFA-4EAF-92B5-FF69A0A7E3F7Q27024239-4FFC0DDE-7527-4BE7-838A-7D898DD12E16Q27332349-AC702536-0F2F-4DD8-B08B-98CBC5512C2EQ30235234-A74D9380-8807-406A-A72C-F16B4BEBF91CQ30316704-FD607540-8DA7-44CB-AE58-824595675597Q30620834-54DE442D-A3A5-4D78-9A63-7314D01E5711Q30762078-77C1FD09-86B4-44B3-8AE0-801340293362Q33462549-B825CB91-D0EA-4A3D-80EC-9E7185D8F43CQ33466628-07846F3B-9DEE-4F0E-821D-E8BE13BACDCFQ33965163-2AACE34F-7787-44B5-9D45-E9705AD79500Q34081740-52F63C19-ECF7-4537-8BED-48008C816BA3Q34377144-93571533-E285-4FBD-A9A7-BB77CF32B1B6Q34420883-960ED147-8BE0-4B03-B667-CD90B30D91BDQ34439828-2FA8FB02-F794-42D1-9DFD-72DADFABB374Q34560412-E8ED824D-7E6C-4D44-B325-6E0DA0CE89C8Q35078712-268F7287-4E07-48F1-A372-C07CE53AF699Q35151791-F9405E6D-87E4-49D3-9087-F2EB34C70575Q35349168-8AAA2B44-88D3-4C41-9C49-76557239E7EFQ35349445-FDDF9973-0505-4578-9189-014E7A0D0DADQ35359719-3EF8A36B-7FBE-49F0-9EC5-CB3E69048021Q35364603-F8FE8BDD-4AB2-43DF-91A4-743CB0C0A509Q35600101-71E2E335-84AF-4D99-9DF2-7FB700A93EA0Q35841129-274F5FD0-C392-4310-A687-825A1875DC10Q35875065-FA141295-21AC-45C6-B9E8-016EF0D2D60EQ36223541-DFD26721-86EE-459C-9BDC-5A8F8AB822C0Q36254638-A894D31C-7651-4C02-9FBB-5BF8CB31BA9DQ36291692-5022C51D-0BFB-47AC-B456-5688B3F474BEQ36377218-0972CB69-5474-4B0D-B255-AD197B504880Q36587015-6C79C079-D009-42DC-AAD0-437503031A46Q36903406-632EF0FD-338E-4176-8EB8-8B4D46696E1FQ37092661-A1C46BC6-C8D7-413D-852E-162CA6312E8DQ37257357-DA2ED77C-276D-4393-AE3B-155A21443D5AQ38249098-700ADFB2-B5A6-4B4C-A4A8-F1E3C60E1CF5Q38255942-CFE4E435-4A1F-4720-B500-3E58E4EDA380Q38264128-B011CB3A-ED6B-41AC-B3E6-FF9E75A98949Q38286331-5FA9D70C-1FDF-49A9-BFA0-534EDDB27689Q38396839-727AA828-339D-4BA1-8F80-E586D8125311Q38417916-CDFBD518-B25F-4E13-A54E-C3CBF4E0B0AFQ38531668-A7682900-92EC-4A8D-B018-BA91C3AEF17EQ38588458-B6331AE4-9DA4-4AE6-B73A-1BE40883E5DE
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Jan Tack
@ast
Jan Tack
@en
Jan Tack
@es
Jan Tack
@sl
type
label
Jan Tack
@ast
Jan Tack
@en
Jan Tack
@es
Jan Tack
@sl
prefLabel
Jan Tack
@ast
Jan Tack
@en
Jan Tack
@es
Jan Tack
@sl
P1006
P214
P1006
P106
P2038
P21
P214
P31
P496
0000-0002-3206-6704
P735
P7859
lccn-n2016183788